2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 3: March 20, 2024 - Highlights from the San Diego Academy Meeting - Our Most Important Learnings
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, March 20, 2024
8 PM ET / 5 PM PT
Highlights From the San Diego Academy Meeting
Part I: Highlights from the San Diego Academy Meeting on Inflammatory Skin Diseases: Atopic dermatitis, Alopecia, Acne/Rosacea, Psoriasis and more
Part II: Highlights from the San Diego Academy Meeting on Pediatric dermatology, Skin cancers, and Aesthetic dermatology
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 21, 2024
March 21, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss current management advancement in dermatology from rashes through tumors
Compare strategies to manage dermatologic conditions from laser treatment through systemic therapies
Identify appropriate treatment options for dermatologic conditions based on patient and disease characteristics
Recognize the nuances of managing dermatologic conditions in skin of color
Underline strategies to optimize management in patients with dermatologic conditions
Illustrate strategies to manage dermatologic conditions effectively in clinical practice
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Hilary Baldwin, MD
Director, Acne Treatment and Research Center
Rutgers Robert Wood Johnson Medical Center
New Brunswick, NJ
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Darrell Rigel, MD, MS
Clinical Professor of Dermatology
New York University
Grossman School of Medicine
New York, NY
Adjunct Professor
UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic
Dallas, TX
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Advisory Board: Bausch, Galderma, Almirall, SUN, La Roche Posay, Cutera
Consultant: Bausch, Galderma. Almirall, Sun, Cutera
Speakers’ Bureau or Honoraria: Bausch, Galderma, Almirall, SUN, La Roche Posay
Consultant: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis, LEO Pharma, Janssen
Speakers’ Bureau or Honoraria: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis
Consultant: Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio
Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly and Company, Incyte, Pfizer Inc, Regeneron and Sanofi Genzyme
Other Financial Benefit: Clinical trial investigator for AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, NIH, Pfizer Inc.
Grant/Research Support: CROMA Pharma, Galderma, Merz
Consultant: CROMA Pharma, Revian, Sensus
Speakers’ Bureau or Honoraria: Allergan, AMP, Galderma, Hugel, Sensus
Grant/Research Support: Castle Biosciences, SciBASE
Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics
Speakers’ Bureau or Honoraria: Castle Biosciences
Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.